TTK Healthcare Limited
TTKHLTCARE · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,409.52. Low-confidence estimate — limited data.
Piotroski F-score 1/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%6.0%
- ✓Low debt (D/E < 0.5)0.02x
- ✕Positive free cash flow
- ✓Revenue growth > 10%14%
- ✓Earnings growing35%
- ✕Net margin ≥ 10%7.7%
- ✓Current ratio > 1.55.91
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✕Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 5.8
- ✕Piotroski ≥ 71/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 5.8.
Weaknesses
- •Low return on equity (6.0%).
- •Price below its 200-day moving average (downtrend).
- •Weak Piotroski score (1/9).
Opportunities
- •Earnings growing (35% YoY).
- •Revenue growing (14% YoY).
- •Trading in our value buy zone versus sector peers.
- •Well off its 52-week high — possible mean-reversion.
- •Trades ~100% below our estimated fair value.
About TTK Healthcare Limited
TTK Healthcare Limited engages in the animal welfare, consumer product, medical device, protective device, food, and other businesses in India. It operates through Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods, and Others segments. The Animal Welfare segment offers various feed supplements, liver correctives, fertility inducers, antibiotics, antiparasiticides, antispasmodics, cervical dilators, cocktail enzymes, etc
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.